Notification, Patent Applications and Use of New Intellectual Property Clause Samples

The "Notification, Patent Applications and Use of New Intellectual Property" clause establishes the obligations of parties to promptly inform each other about the creation of new intellectual property and any related patent filings. Typically, this clause requires that any inventions or discoveries made during the course of a project be disclosed to the relevant party, and it may outline procedures for filing patent applications, including who has the right or responsibility to file and how costs are managed. Its core function is to ensure transparency and proper management of new intellectual property, preventing disputes over ownership and use while protecting the interests of all parties involved.
Notification, Patent Applications and Use of New Intellectual Property. Recipient will promptly notify Provider in writing of any New Intellectual Property and will be free to use and exploit the New Intellectual Property (but not to assign or otherwise transfer the Modifications except with the written approval of Provider or as permitted under this Materials Transfer Agreement). Recipient may file patent application(s) claiming New Intellectual Property, but will give Provider at least thirty (30) days written notice prior to filing such patent application(s). In the case where Company is the Recipient, Recipient hereby grants Provider a non-exclusive, non-transferable, non-sublicensable, perpetual, royalty-free licence to use the New Intellectual Property for educational and non-clinical, non-commercial research purposes only, and in the case where Institution is the Recipient, Recipient hereby grants Provider a non-exclusive, non-transferable, sublicensable, perpetual, worldwide, royalty-free licence to use the New Intellectual Property for internal non-clinical research purposes only, including the right of Provider to sublicense the New Intellectual Property to its collaborators at academic organizations and clinical research organizations in support of Provider’s internal research programs provided that such sublicense agreements are on terms and conditions consistent with the terms and conditions of this Materials Transfer Agreement.
View SourceView Similar (2)
Notification, Patent Applications and Use of New Intellectual Property. Recipient will promptly notify Provider in writing of any New Intellectual Property and will be free to use and exploit the New Intellectual Property (but not to assign or otherwise transfer the Modifications except with the written approval of Provider or as permitted under this Agreement). Recipient may file patent applications(s) claiming New Intellectual Property, but will give Provider at least thirty (30) days written notice prior to filing such patent application(s). Recipient hereby grants Provider a non-exclusive, non-transferable, perpetual, worldwide, royalty-free license to use the New Intellectual Property for internal research and teaching purposes only.
View SourceView Similar (2)
Notification, Patent Applications and Use of New Intellectual Property. Recipient will promptly notify Provider in writing of any New Intellectual Property and will be free to use and exploit the New Intellectual Property (but not to assign or otherwise transfer the Modifications except with the written approval of Provider or as permitted under this Materials Transfer Agreement). Recipient may file patent application(s) claiming New Intellectual Property, but will give Provider at least thirty (30) days written notice prior to filing such patent application(s). Recipient hereby grants Provider a non-exclusive, non- transferable, worldwide, royalty-free licence to use the New Intellectual Property, to be provided under a seprate Material Transfer Agreement referencing the terms herein, for internal non-clinical research and teaching purposes only.
View Source

Related to Notification, Patent Applications and Use of New Intellectual Property

  • Patents and Patent Applications To the Company’s knowledge, all patents and patent applications owned by or licensed to the Company or under which the Company has rights have been duly and properly filed and maintained; to the knowledge of the Company, the parties prosecuting such applications have complied with their duty of candor and disclosure to the USPTO in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which could reasonably be expected to preclude the grant of a patent in connection with any such application or could reasonably be expected to form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications.

  • Patent Applications It is understood by the parties that, pursuant to the Baylor Technology Transfer Agreement, MAS has the initial responsibility for filing, prosecution and maintenance of Patents and Patent Applications covering the Baylor Technology. The parties agree that, as between MAS and IllumeSys, MAS shall be responsible for deciding whether and how to file, prosecute and maintain the Patents and Patent Applications, provided that:

  • Intellectual Property, Inventions and Patents Executive acknowledges that all discoveries, concepts, ideas, inventions, innovations, improvements, developments, methods, designs, analyses, drawings, reports, patent applications, copyrightable work and mask work (whether or not including any confidential information) and all registrations or applications related thereto, all other proprietary information and all similar or related information (whether or not patentable) which relate to Parent’s or any of its Subsidiaries’ actual or anticipated business, research and development or existing or future products or services and which are conceived, developed or made by Executive (whether alone or jointly with others) while employed by the Company and its Subsidiaries, whether before or after the date of this Agreement (“Work Product”), belong to Parent, the Company or such Subsidiary. Executive shall promptly disclose such Work Product to the Board and, at the Company’s expense, perform all actions reasonably requested by the Board (whether during or after the Employment Period) to establish and confirm such ownership (including, without limitation, assignments, consents, powers of attorney and other instruments).

  • Patents and Intellectual Property Rights Recipients are subject to the ▇▇▇▇-▇▇▇▇ Act, 35 U.S.C. § 200 et seq, unless otherwise provided by law. Recipients are subject to the specific requirements governing the development, reporting, and disposition of rights to inventions and patents resulting from federal financial assistance awards located at 37 C.F.R. Part 401 and the standard patent rights clause located at 37 C.F.R. § 401.14.

  • INTELLECTUAL PROPERTY RIGHTS - INVENTION AND PATENT RIGHTS A. General 1. NASA has determined that 51 U.S.C. § 20135(b) does not apply to this Agreement. Therefore, title to inventions made (conceived or first actually reduced to practice) under this Agreement remain with the respective inventing party(ies). No invention or patent rights are exchanged or granted under this Agreement, except as provided herein.